An interventional study of FlowOx™ in Multiple Sclerosis, Spasticity, Muscle and Pain, sponsored by Otivio AS. Completed at 1 site in Norway. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-19.
Sponsored by Otivio AS · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 56 studies in Multiple Sclerosis with a site in Norway — 2 open to participants now, 9 under way, 3 of them phase 3. Multiple Sclerosis · Norway.
Among the 56 studies in Multiple Sclerosis with a site in Norway, this one is the 42nd largest by enrollment of the 43 interventional ones that give a count, is one of 3 that started in 2021, is one of 9 with no phase, and was the 45th registered.
3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →2 of the 56 studies in Multiple Sclerosis with a site in Norway are open now. Recruiting first, the newest first:
Oslo University Hospital · Sites in Norway
Ages 50–80
Haukeland University Hospital · Sites in Norway
Ages 18–65
A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →
Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
56 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 10 · Phase 3 17 · Phase 4 6
First in 2002; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 10 is below the median of 50 across 2,208 interventional studies indexed under Multiple Sclerosis.
Median enrollment 300 across the 43 interventional studies, 599 across the 13 observational. Of the 41 that completed or were terminated, 20 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 56 have an industry lead sponsor. The 10 most frequent:
Otivio AS is the lead sponsor of 5 studies on the registry; none are open to participants now.
Otivio AS has 3 studies filed under Multiple Sclerosis — fewer than ten, so there is no comparison to draw.
1 of the studies in Multiple Sclerosis with a site in Norway that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05740722Haukeland University HospitalNicotinamide Riboside Supplementation In Progressive Multiple Sclerosis | 2027-08-01 |
Add it to your calendar (.ics) → With an account.
Among the 56 studies in Multiple Sclerosis with a site in Norway, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a descriptive, prospective, non-controlled clinical investigation to be conducted on approximately 10 enrolled subjects at one site at Haukeland University Hospital in Bergen, Norway. The target subjects are male or female, 18-70 years, diagnosed with MS according to revised McDonald criteria (9) with spasticity and pain associated with the spasticity. Spasticity is evaluated based on self-reported spasticity using the numerical rating scale (NRS) which describes the average score of spasticity over the last 24 hours at >4 (where the scale scores spasticity from 0-10, where 0 is no spasticity, and 10 is worst possible spasticity), - combined with pain in the lower extremities last 24 hours. The pilot investigation is done to evaluate if FlowOx2.0™ can be used to treat spasticity with concomitant pain in patients with multiple sclerosis, using intermittent negative pressure affecting arteriovenous reflex.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Each participating subject will be provided with one FlowOx™ system, which will be used about 1 hour per day every day of the week for a 4-week period with the option to extend the treatment time to up to 6 months if the patients would like to continue.
Device: FlowOx™
The FlowOx™ system generates a negative oscillating pressure which cause rapid fluctuations in blood flow in the leg and foot.
Self-Reported Spasticity, using Numerical Rating Scale:
The unabbreviated scale title: Numerical Rating Scale The minimum and maximum values: 0, 10 Higher scores mean a worse outcome. To evaluate change in self-reported spasticity using the numerical rating scale (NRS) over the last 24 hours after daily 1-hour self-treatment with FlowOx from baseline to week 4
Time frame: 4 weeks
Desire to continue treatment
Proportion of patients who wish to continue treatment with FlowOx beyond 4 weeks
Time frame: 4 weeks
Self-Reported Spasticity, using Numerical Rating Scale
The unabbreviated scale title: Numerical Rating Scale The minimum and maximum values: 0, 10 Higher scores mean a worse outcome. To evaluate change in self-reported spasticity using the numerical rating scale (NRS) over the last 24 hours after daily 1-hour self-treatment with FlowOx compared to baseline
Time frame: 3 months, 6 months
Spasticity - modified Ashworth Scale
The unabbreviated scale title: Modified Ashworth Scale The minimum and maximum values: 0, 4 Higher scores mean a worse outcome. Change in spasticity measured by modified Ashworth scale from baseline to week 4, month 3 and month 6.
Time frame: 4 weeks, 3 months and 6 months
Self-reported pain using Numerical Rating Scale
The unabbreviated scale title: Numerical Rating Scale The minimum and maximum values: 0, 10 Higher score means worse pain. To evaluate change in self-reported spasticity using the numerical rating scale (NRS) over the last 24 hours after daily 1-hour self-treatment with FlowOx from baseline.
Time frame: 4 weeks, 3 months and 6 months
T25-FW
Change of Timed 25-Foot Walk (T25-FW) from baseline
Time frame: 4 weeks, 3 months, 6 months
Expanded Disability Status Scale
The unabbreviated scale title: Expanded Disability Status Scale The minimum and maximum values: 0, 10 Higher score means worse disability status. Change of functional score measured by Expanded Disability Status Scale (EDSS) and compared to baseline
Time frame: 4 weeks, 3 months, 6 months
Self-reported sleep (NRS)
The unabbreviated scale title: Numerical Rating Scale The minimum and maximum values: 0, 10 Higher score means worse sleep. Change in self reported sleep quality will measured by (NRS) and compared to baseline
Time frame: 4 weeks, 3 months, 6 months
Hospital Anxiety and Depression Scale
The unabbreviated scale title: Hospital Anxiety and Depression Scale The minimum and maximum values: 0, 3 Higher score means worse outcome. The Scale has 14 questions, the scores will be summarized at each time point and compared to baseline
Time frame: 4 weeks, 3 months, 6 months
Fatigue Scale for Motor and Cognitive Functions
The unabbreviated scale title: Fatigue Scale for Motor and Cognitive Functions (FSMC) The FSMC is an assessment of MS-related cognitive and motor fatigue. A Likert-type 5-point scale (ranging from 'does not apply at all' to 'applies completely') produces a score between 1 and 5 for each scored question. Thus minimum value is 20 (no fatigue at all) and maximum value is 100 (severest grade of fatigue). Two subscales (mental and physical fatigue) can be made. Items included in the subscale mental are 1-4-7-8-11-13-15-17-18-20 and items included in the subscale physical are 2-3-5-6-9-10-12-14-16-19. Changes in the scores will be compared to baseline.
Time frame: 4 weeks, 3 months, 6 months
Multiple Sclerosis Impact Scale (MSIS-29)
The unabbreviated scale title: Multiple Sclerosis Impact Scale The minimum and maximum values: 1, 5 Higher score means worse condition. There are 29 questions, change in reported status will be compared to baseline
Time frame: 4 weeks, 3 months, 6 months
SDMT
Change in cognition measured by the Symbol Digit Modalities Test (SDMT) The Symbol Digit Modalities Test (SDMT) is a cognitive task. It consists of a sheet of paper with, at the top, a sequence of nine symbols and nine corresponding numbers (key). The task sequence consists of a series of symbols, each with a blank space underneath. Within a 90-second time limit the subject is required, consulting the key as necessary, to insert the numbers associated with the symbols. Changes in the performance will be compared to baseline.
Time frame: 4 weeks, 3 months, 6 months
Change in medication
Medication used by the patients at the start of the trial will be recorded. Any change in frequency of use or dose of the medication to treat spasticity an/or pain will be recorded and compared to baseline.
Time frame: 4 weeks, 3 months and 6 monhts
Compliance
"Compliance" / use of FlowOx, is automatically logged in the machine and will be read after 4 weeks
Time frame: 4 weeks, 3 months, 6 months
Safety- Incidence of device related adverse and serious adverse events
The number and type of adverse events and servere device related events during the study will be recorded. To evaluate safety of FlowOx by assessment of device deficiencies and adverse events, non-serious and serious, rated for causality
Time frame: 4 weeks, 3 months, 6 months
Plan to share: No
No publications or documents are linked to this record.
Ran from May 2021 to primary completion in Sep 2022, 16 months.
Of 874 interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's 16 months is below that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 19, 2026: primary completion Dec 2021 → Sep 2022 and completion Dec 2021 → Sep 2022.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Otivio AS